• Explore /
  • Poster
  • / Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).

Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).

Abstract Poster

Authors

null

Ahmad Awada

Jules Bordet Institute, Bruxelles, Belgium

Ahmad Awada , Ramon Colomer , Igor Bondarenko , Kenichi Inoue , Rajendra A. Badwe , Georgia Demetriou , Xiaojia Wang , Vitaly Smirnov , Soo-Chin Lee , Ajay O. Mehta , Sung-Bae Kim , Zhen-Zhou Shen , Thomas Denis Bachelot , Chanchal Goswami , S. V. S. Deo , Ron Bose , Alvin Wong , Feng Xu , Richard Bryce , Lisa A. Carey

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Clinical Trial Registration Number

NCT00915018

Citation

J Clin Oncol 33, 2015 (suppl; abstr 610)

DOI

10.1200/jco.2015.33.15_suppl.610

Abstract #

610

Poster Bd #

99

Abstract Disclosures

Similar Posters

First Author: Min Yan

First Author: Chunfang Hao

First Author: Shannon Puhalla

First Author: Rachel A. Freedman